Pediatric and Geriatric Clinical Trials

PK/PD Modeling for Age-Based Dose Adjustments

Posted on digi By digi

In drug development, children and older adults are often excluded from early-phase trials. As a result, clinicians rely heavily on modeling and simulation to predict safe and effective doses for these age groups. Pharmacokinetics (PK) describes how the body handles the drug (absorption, distribution, metabolism, elimination), while pharmacodynamics (PD) describes the drug’s effects on the body. Age significantly influences both — from enzyme ontogeny in neonates to reduced renal clearance in the elderly.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Pediatric Safety Reporting Standards (e.g., ICH E11A)

Posted on digi By digi

Pediatric safety reporting standards translate high‑level ethics into daily trial actions. In ICH E11/E11A framing, children are not “small adults”; organ maturation, dynamic growth, and limited communication require age‑fit definitions, measurements, and timelines. Safety reporting in pediatrics encompasses accurate capture of adverse events (AEs), precise identification of serious adverse events (SAEs), causality/expectedness assessment against an age‑appropriate Reference Safety Information (RSI), rapid expedited reporting for suspected unexpected serious adverse reactions (SUSARs), and aggregate evaluation that includes growth and neurodevelopment. These expectations hold across neonates, infants, children, and adolescents, but the way you meet them changes with age: a neonate’s apnea cluster or feeding intolerance may be the earliest signal of drug‑related toxicity, while an adolescent can self‑report early neurocognitive changes.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Managing Adverse Events in Geriatric Populations

Posted on digi By digi

Adverse event (AE) management in geriatric clinical trials is not a simple copy of adult protocols. Aging narrows physiologic reserve across systems—renal filtration declines, hepatic blood flow drops, baroreflexes blunt, and bone marrow recovery slows. Layer in multimorbidity and polypharmacy, and the same exposure that is well tolerated in a 55‑year‑old may precipitate orthostatic hypotension, delirium, or a fall in an 82‑year‑old. These outcomes may not register as high‑grade CTCAE laboratory events, yet they drive hospitalizations, loss of independence, and mortality in seniors. AE management must therefore center on functionally significant signs and not just labs: dizziness on standing, new confusion, slowed gait, or appetite/sleep changes can be sentinel harms that demand action long before creatinine or hemoglobin cross standard thresholds.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Case Study: Dose Escalation in Pediatric Rare Disease Trials

Posted on digi By digi

This case study describes a first‑in‑pediatrics, multicenter dose‑escalation trial for an oral small molecule intended to up‑regulate a deficient metabolic pathway in a rare autosomal recessive disorder. The syndrome manifests in neonates to early childhood with failure to thrive, intermittent hypoglycemia, and neurodevelopmental delay. An adult program does not exist; only preclinical juvenile toxicology and a small compassionate‑use set (n=6, mixed ages) inform risk. The primary objective is to identify a pediatric recommended Phase 2 dose (pRP2D) by balancing safety, pharmacokinetics (PK), and pharmacodynamic (PD) target engagement. Secondary objectives include characterization of exposure–response for safety (e.g., hypoglycemia, transaminase elevations) and early PD signal (a plasma metabolite ratio). Exploratory objectives track growth velocity and caregiver‑reported function.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Community-Based Recruitment for Pediatric Trials

Posted on digi By digi

Recruiting children and adolescents into clinical trials requires more than flyers and physician referrals. Families weigh logistics, perceived risk, school schedules, culture, language, and a community’s historic experience with health systems. Community-based recruitment meets families where they are—clinics, schools, faith centers, early-childhood programs, youth clubs—and translates protocol value into everyday terms. Done well, it expands representation across socioeconomic, racial/ethnic, and rural/urban lines, improving external validity and meeting regulatory expectations for diversity and inclusion. Done poorly, it slows timelines, amplifies screen failures, and raises ethics concerns about undue influence or opaque messaging.
Click to read the full article.

Pediatric and Geriatric Clinical Trials, Recruitment Strategies

Engaging Pediatricians and Geriatricians in Recruitment Campaigns

Posted on digi By digi

Pediatricians and geriatricians sit at the center of healthcare decisions for families and older adults. They balance clinical priorities, limited time, and deep relationships with patients. If your trial’s outreach bypasses these clinicians, referrals stall and diversity suffers. Parents lean on pediatricians to translate science into day‑to‑day implications—missed school, blood draws, taste of formulations—while older adults ask geriatricians whether participation will threaten independence, interact with polypharmacy, or increase fall risk. Engagement campaigns must therefore start by solving the clinician’s problems: making referral fast, ethically clean, clinically relevant, and low burden. It’s not about “selling” a study; it’s about enabling good care with research as an option.
Click to read the full article.

Pediatric and Geriatric Clinical Trials, Recruitment Strategies

Caregiver Engagement to Improve Enrollment Rates

Posted on digi By digi

In both pediatric and geriatric clinical trials, the pivotal decision maker is often not the patient but the caregiver—parents, adult children, spouses, or legal guardians. They filter scientific promises through everyday life: school schedules, transportation, home caregiving duties, and fears about procedures. Programs that focus exclusively on physician referrals or digital ads typically stall because they fail to answer a caregiver’s first questions: “How much time will this take? Will it hurt? What happens if we change our minds?” Caregiver engagement reframes recruitment as a service, not a sales pitch: minimize burden, explain protections in plain language, and demonstrate that operations are built around family realities.
Click to read the full article.

Pediatric and Geriatric Clinical Trials, Recruitment Strategies

Use of Technology in Age-Specific Recruitment

Posted on digi By digi

Digital tools can widen access to clinical trials, but one size never fits all—especially across pediatrics and geriatrics. Caregivers, teens, and older adults interact with technology differently. The same Instagram post that reaches adolescents may miss caregivers who live in WhatsApp, and senior participants might prefer patient portals, SMS, or phone calls over apps. Age‑specific design respects these preferences while staying ethical and regulator‑aligned. The goal is to increase equitable reach without adding coercion, confusion, or privacy risk. Practically, that means building multiple, parallel digital pathways—each with clear consent‑to‑contact and privacy protections—that converge on a human conversation when interest is high.
Click to read the full article.

Pediatric and Geriatric Clinical Trials, Recruitment Strategies

Reducing Trial Burden for Elderly Participants

Posted on digi By digi

Older adults are often underrepresented in clinical research, not due to lack of interest, but because trial protocols create unnecessary burdens. These can include frequent site visits, long travel distances, complex consent documents, and invasive sampling schedules. Age-related mobility limitations, sensory impairments, comorbidities, and reliance on caregivers compound these challenges. For instance, requiring weekly on-site blood draws can be prohibitive for a participant with limited transportation and multiple chronic conditions. Trial designers must distinguish between scientifically necessary requirements and those that can be adapted or removed without compromising data integrity.
Click to read the full article.

Pediatric and Geriatric Clinical Trials, Recruitment Strategies

Transportation and Visit Flexibility for Pediatric and Geriatric Subjects

Posted on digi By digi

In pediatric and geriatric studies, most screen failures and early withdrawals aren’t about science—they’re about logistics. Parents juggle school pickups, shift work, and siblings; older adults juggle mobility, caregiver availability, and comorbid appointments. A protocol that expects weekday morning hospital visits and full venipuncture panels is unintentionally exclusionary. The remedy is to treat transportation and scheduling as primary design variables rather than afterthoughts. That means budgeting for ride solutions, building after‑school and weekend sessions, enabling telehealth where clinically sound, and using home or community clinics for low‑acuity assessments. Doing so expands geographic reach, improves equity, and reduces differential dropout that can bias outcomes.
Click to read the full article.

Pediatric and Geriatric Clinical Trials, Recruitment Strategies